Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Raul Veroz Gonzalez"'
Autor:
Beatriz Valls-Espinosa, Verónica Rodriguez-Mendez, J Francisco, José Luis Martín-Varillas, Lara Sánchez Bilbao, Ángel Mora, Arantxa Conesa, Diana Peiteado, Toyos Sáenz de Miera, Margarita Sánchez Orgaz, Eva Tomero, Elia Valls-Pascual, O. Maiz-Alonso, Diana Prieto-Peña, Ana Blanco, Raul Veroz Gonzalez, Ignacio Torre-Salaberri, Miguel A. González-Gay, Belén Atienza-Mateo, Santos Castañeda, Ricardo Blanco, Vega Jovani, Manuel Vidal Fernández Fernández, Valvanera Pinillos, Monica Calderón-Goercke, R. Demetrio-Pablo, J. Antonio Troyano, Vanesa Calvo-Río, I. González-Mazón, Ángel García-Aparicio, Elena Aurrecoechea
Publikováno v:
Abstracts Accepted for Publication.
Background Graves’ orbitopathy (GO) is the most common and important extrathyroidal manifestation of Graves’ disease. Corticostereoids and conventional immunosuppressors are not always effective or well tolerated. The IL-6 receptor antibody tocil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f58548d36c9c57243078cfe87118f5d4
https://doi.org/10.1136/annrheumdis-2019-eular.1628
https://doi.org/10.1136/annrheumdis-2019-eular.1628
Autor:
Belén Atienza-Mateo, Esteban Rubio Romero, Ricardo Blanco, Miguel A. González-Gay, Luis Fernández-Dominguez, B. Joven-Ibáñez, Beatriz Arca, Alfonso Corrales, Clara Ventin-Rodriguez, José Luis Martín-Varillas, Jose Campos Esteban, Antia Crespo Golmar, Francisco Ortiz-Sanjuán, Maria Jose Moreno, Manuel Moreno, Eva Galindez, O. Maíz, Rafael Melero, Agusti Sellas-Fernández, Raul Veroz Gonzalez, Enrique Raya, Roberto Daniel Gonzalez Benitez, Olga Rusinovich, Alejandro Escudero Contreras, Emma Beltrán, Vanesa Calvo-Río, Natalia Palmou-Fontana, Javier Loricera, Ximena Elizabeth Larco Rojas, María-Luisa Peral
Publikováno v:
Abstracts accepted for Publication.
Background: Tofacitinib (TOFA) is the first inhibitor of JAK kinases with approval for the treatment of psoriatic arthritis (PsA) in Europe (July 2018)1. ToFA has shown efficacy in refractory patients to anti-TNF2. Objectives: A) to assess efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bacfa1479a5769dfa23f37f5a822b1c
https://doi.org/10.1136/annrheumdis-2019-eular.7803
https://doi.org/10.1136/annrheumdis-2019-eular.7803